2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatientsGene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Oliveira-Costa J, de Carvalho A, da Silveira G, Amaya P, Wu Y, Park K, Gigliola M, Lustberg M, Buim M, Ferreira E, Kowalski L, Chalmers J, Soares F, Carraro D, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015, 6: 20902-20920. PMID: 26041877, PMCID: PMC4673238, DOI: 10.18632/oncotarget.3939.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAutoimmune DiseasesB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesCytoplasmDNA-Binding ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsNeoplastic Cells, CirculatingOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsTissue BanksTreatment OutcomeConceptsOral squamous cell carcinomaPD-L1Tumor sizePerineural invasionPrimary tumorAdvanced oral squamous cell carcinomaTumor cellsSquamous cell carcinoma developmentStrong cytoplasmatic expressionPD-L1 positivityDisease-specific survivalOral squamous cell carcinoma developmentPD-L1 expressionIndependent prognostic factorLymph node metastasisT cell activitySquamous cell carcinomaSub-classify patientsSpecific survivalNode metastasisPD-1Prognostic factorsPoor prognosisAutoimmune diseasesCell carcinoma
2013
Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors
Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg M, Ray A, Pompili V, Shapiro C, Das H. Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors. International Journal Of Cancer 2013, 133: 2133-2144. PMID: 23595559, PMCID: PMC3939063, DOI: 10.1002/ijc.28217.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisBiomarkers, TumorBlotting, WesternBreast NeoplasmsCell CycleCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansReceptors, Antigen, T-Cell, gamma-deltaT-Lymphocyte SubsetsTumor Cells, CulturedTumor MicroenvironmentConceptsΓδ T cellsVγ2Vδ2 T cellsT cellsApoptosis-related moleculesAntineoplastic effectsVγ2Vδ2 T-cell subsetTumor cellsInfiltration of tumorsMICA/BT cell subsetsHuman Vγ2Vδ2 T cellsBreast cancer growthExpression levelsInnate immune systemMolecular signalingBreast tumor cellsMDA-MB-231Resistant cell linesCell subsetsSurface expression levelsCancer growthImmune systemTumor growthMalignant transformationTumor progression